Split History
ETFs Holding UTHR »    UTHR Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection for treatment of high-risk neuroblastoma. Co. also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. Co. also engages in organ transplantation-related technologies. According to our UTHR split history records, United Therapeutics has had 1 split.
UTHR split history picture
United Therapeutics (UTHR) has 1 split in our UTHR split history database. The split for UTHR took place on September 23, 2009. This was a 2 for 1 split, meaning for each share of UTHR owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as United Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the UTHR split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into United Therapeutics shares, starting with a $10,000 purchase of UTHR, presented on a split-history-adjusted basis factoring in the complete UTHR split history. UTHR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/08/2009
End date: 12/06/2019
Start price/share: $44.43
End price/share: $91.61
Dividends collected/share: $0.00
Total return: 106.19%
Average Annual Total Return: 7.50%
Starting investment: $10,000.00
Ending investment: $20,610.32
Years: 10.00
Date Ratio
09/23/20092 for 1
UTHR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

VAR Split History
VBIV Split History
VICL Split History
VIV Split History
VIVO Split History
VLRX Split History
VRTX Split History
VSCP Split History
VVUS Split History
WAT Split History

Also explore: UTHR shares outstanding history

iMedia Brands, Inc. (IMBI)
Akers Biosciences, Inc. (AKER)
NeuroMetrix, Inc. (NURO)
TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
Cancer Genetics, Inc. (CGIX)
Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3X Shares (GUSH)
Kingold Jewelry, Inc. (KGJI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

UTHR Insider Buying

UTHR Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.